Autoinflammatory Features in Gouty Arthritis
暂无分享,去创建一个
A. Doria | P. Galozzi | F. Oliviero | P. Sfriso | S. Bindoli | A. Doria
[1] A. Scanu,et al. M2 macrophages as resolvers of crystal-induced inflammation. , 2021, Rheumatology.
[2] S. Tripodi,et al. NEUTROPHIL EXTRACELLULAR TRAPS RELEASE IN GOUT AND PSEUDOGOUT DEPENDS ON THE NUMBER OF CRYSTALS REGARDLESS OF LEUKOCYTE COUNT. , 2021, Rheumatology.
[3] Ying Wang,et al. Discovery of a novel rice-derived peptide with significant anti-gout potency. , 2020, Food & function.
[4] Geun-Shik Lee,et al. Riboflavin, vitamin B2, attenuates NLRP3, NLRC4, AIM2, and non-canonical inflammasomes by the inhibition of caspase-1 activity , 2020, Scientific Reports.
[5] L. Joosten,et al. The role of interleukin-1 family members in hyperuricemia and gout. , 2020, Joint bone spine.
[6] L. Punzi,et al. One year in review 2020: gout. , 2020, Clinical and experimental rheumatology.
[7] J. Nan,et al. Management of Gout-associated MSU crystals-induced NLRP3 inflammasome activation by procyanidin B2: targeting IL-1β and Cathepsin B in macrophages , 2020, Inflammopharmacology.
[8] M. Kolber,et al. Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.
[9] Chongge You,et al. The Role of Non-Coding RNAs in Gout. , 2020, Endocrinology.
[10] W. Wan,et al. Interleukin-37 contributes to the pathogenesis of gout by affecting PDZ domain-containing 1 protein through the nuclear factor-kappa B pathway , 2020, The Journal of international medical research.
[11] Bin Wang,et al. Role of T cells in the pathogenesis and treatment of gout. , 2020, International immunopharmacology.
[12] H. Duez,et al. Circadian Control of Inflammasome Pathways: Implications for Circadian Medicine , 2020, Frontiers in Immunology.
[13] Lingyi Kong,et al. MicroRNA and long noncoding RNA involvement in gout and prospects for treatment. , 2020, International immunopharmacology.
[14] R. Ramonda,et al. Phagocytosis and inflammation in crystal-induced arthritis: a synovial fluid and in vitro study. , 2020, Clinical and Experimental Rheumatology.
[15] Lijun Li,et al. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. , 2020, American journal of translational research.
[16] Chung-Jen Chen,et al. Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout , 2020, International journal of molecular sciences.
[17] J. Bylund,et al. In Vivo Transmigrated Human Neutrophils Are Highly Primed for Intracellular Radical Production Induced by Monosodium Urate Crystals , 2020, International journal of molecular sciences.
[18] G. Guyatt,et al. 2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis care & research.
[19] L. Joosten,et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. , 2020, The Lancet Rheumatology.
[20] Wenjiao Jiang,et al. P2Y14 receptor has a critical role in acute gouty arthritis by regulating pyroptosis of macrophages , 2020, Cell Death & Disease.
[21] A. Doria,et al. Autoinflammatory Mechanisms in Crystal-Induced Arthritis , 2020, Frontiers in Medicine.
[22] Chang Hu,et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, Journal of Clinical Virology.
[23] Joo Young Lee,et al. Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3‐Driven Inflammation and Gouty Arthritis , 2020, Arthritis & rheumatology.
[24] A. Hoischen,et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout , 2020, Annals of the rheumatic diseases.
[25] Boyi Liu,et al. Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis , 2019, British journal of pharmacology.
[26] L. Rohrer,et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation , 2019, Nature Immunology.
[27] W. Taylor,et al. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. , 2019, Seminars in arthritis and rheumatism.
[28] L. Punzi,et al. Polydatin and Resveratrol Inhibit the Inflammatory Process Induced by Urate and Pyrophosphate Crystals in THP-1 Cells , 2019, Foods.
[29] Mei Zeng,et al. Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage , 2019, Arthritis Research & Therapy.
[30] S. Benkő,et al. The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. , 2019, Archives of biochemistry and biophysics.
[31] Xizhe Li,et al. Inflammasome inhibitors: promising therapeutic approaches against cancer , 2019, Journal of Hematology & Oncology.
[32] Jiao Luo,et al. Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout , 2019, Journal of immunology research.
[33] C. Pellegrini,et al. Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases , 2019, International journal of molecular sciences.
[34] T. Merriman,et al. Genetic advances in gout: potential applications in clinical practice , 2019, Current opinion in rheumatology.
[35] M. Netea,et al. Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression , 2019, Arthritis Research & Therapy.
[36] F. Salehzadeh,et al. Familial Mediterranean Fever Gene Mutations and Gout as an Auto-Inflammatory Arthropathy , 2019, Medical archives.
[37] Hao Wu,et al. LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. , 2019, Biochimie.
[38] J. Schulz,et al. α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1–42-stimulated murine astrocytes , 2018, Journal of Neuroinflammation.
[39] C. Goh,et al. Back pain and fever: when the diagnosis becomes crystal clear , 2018, Internal medicine journal.
[40] L. Punzi,et al. Anti-inflammatory effects of polyphenols in arthritis. , 2018, Journal of the science of food and agriculture.
[41] T. Merriman,et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis , 2018, Annals of the rheumatic diseases.
[42] Jan-Gowth Chang,et al. ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study , 2018, Scientific Reports.
[43] E. Matisoo-Smith,et al. Mitochondrial genetic variation and gout in Māori and Pacific people living in Aotearoa New Zealand , 2017, Annals of the rheumatic diseases.
[44] Jingguo Zhou,et al. Invariant Natural Killer T Cells Ameliorate Monosodium Urate Crystal-Induced Gouty Inflammation in Mice , 2017, Front. Immunol..
[45] F. Martinon,et al. Inflammation in gout: mechanisms and therapeutic targets , 2017, Nature Reviews Rheumatology.
[46] R. Wu,et al. MicroRNA-488 and -920 regulate the production of proinflammatory cytokines in acute gouty arthritis , 2017, Arthritis Research & Therapy.
[47] R. Terkeltaub. What makes gouty inflammation so variable? , 2017, BMC Medicine.
[48] Xiang-Pei Li,et al. Single nucleotide polymorphisms associated with P2X7R function regulate the onset of gouty arthritis , 2017, PloS one.
[49] H. Anders,et al. Molecular Pathophysiology of Gout. , 2017, Trends in molecular medicine.
[50] A. Scanu,et al. How Factors Involved in the Resolution of Crystal-Induced Inflammation Target IL-1β , 2017, Front. Pharmacol..
[51] C. Zeiss,et al. β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares. , 2017, Cell reports.
[52] C. Queiroz-Junior,et al. Annexin A1 promotes timely resolution of inflammation in murine gout , 2017, European journal of immunology.
[53] Yun-Shien Lee,et al. Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis , 2016, Rheumatology.
[54] A. Karaarslan,et al. Prevalence and significance of MEFV gene mutations in patients with gouty arthritis , 2016, Rheumatology International.
[55] L. Joosten,et al. Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. , 2016, Rheumatology.
[56] Rostyslav Bilyy,et al. Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis , 2016, Nature Communications.
[57] L. Joosten,et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout , 2015, Arthritis Research & Therapy.
[58] J. Schifferli,et al. Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome , 2015, Annals of the rheumatic diseases.
[59] Frank E Corrigan,et al. Polyarticular Gout Flare Masquerading as Sepsis. , 2015, The American journal of medicine.
[60] Shiguo Liu,et al. The rs7517847 polymorphism in the IL-23R gene is associated with gout in a Chinese Han male population , 2015, Modern rheumatology.
[61] Changgui Li,et al. CARD8 rs2043211 Polymorphism is Associated with Gout in a Chinese Male Population , 2015, Cellular Physiology and Biochemistry.
[62] P. A. Crawford,et al. Ketone body β-hydroxybutyrate blocks the NLRP3 inflammasome-mediated inflammatory disease , 2015, Nature Medicine.
[63] O. Shaw,et al. Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals , 2015, Annals of the rheumatic diseases.
[64] N. Dalbeth,et al. Mechanism of action of colchicine in the treatment of gout. , 2014, Clinical therapeutics.
[65] D. Boumpas,et al. Neutrophil extracellular traps regulate IL-1β-mediated inflammation in familial Mediterranean fever , 2014, Annals of the rheumatic diseases.
[66] T. Harrer,et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines , 2014, Nature Medicine.
[67] Zhigang Tian,et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. , 2013, Immunity.
[68] Mei Zeng,et al. Association of TLR4 Gene rs2149356 Polymorphism with Primary Gouty Arthritis in a Case-Control Study , 2013, PloS one.
[69] S. Liu,et al. IL-8 –251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population , 2013, Scandinavian journal of rheumatology.
[70] R. Terkeltaub,et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator , 2013, Arthritis Research & Therapy.
[71] H. Schumacher,et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.
[72] D. Boumpas,et al. Neutrophil Extracellular Trap Formation Is Associated with IL-1β and Autophagy-Related Signaling in Gout , 2011, PloS one.
[73] Cheng-Han Wu,et al. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3 , 2011, Annals of the rheumatic diseases.
[74] C. Mancuso,et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. , 2010, Seminars in arthritis and rheumatism.
[75] M. Oosting,et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. , 2010, Arthritis and rheumatism.
[76] A. So,et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.
[77] A. So,et al. Gout. Mechanisms of inflammation in gout , 2010, Arthritis research & therapy.
[78] L. Punzi,et al. High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals , 2010, Arthritis research & therapy.
[79] L. Joosten,et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. , 2009, Arthritis and rheumatism.
[80] Y. Ko,et al. The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout. , 2007, Rheumatology.
[81] J. Tschopp,et al. A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.
[82] R. Terkeltaub,et al. Engagement of CD14 Mediates the Inflammatory Potential of Monosodium Urate Crystals1 , 2006, The Journal of Immunology.
[83] Dennis McGonagle,et al. A Proposed Classification of the Immunological Diseases , 2006, PLoS medicine.
[84] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[85] N. Dalbeth,et al. Mechanisms of inflammation in gout. , 2005, Rheumatology.
[86] H. Schumacher,et al. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. , 1993, Arthritis and rheumatism.
[87] C. Dubois,et al. Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action , 1990, The Journal of experimental medicine.
[88] S. Skrede,et al. Beta-Hemolytic Streptococci and Necrotizing Soft Tissue Infections. , 2020, Advances in experimental medicine and biology.
[89] D. Kastner. Autoinflammation: Past, Present, and Future , 2019, Textbook of Autoinflammation.
[90] S. Steiger,et al. Mechanisms of Spontaneous Resolution of Acute Gouty Inflammation , 2013, Current Rheumatology Reports.
[91] T. Matsui,et al. Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. , 2003, Arthritis and rheumatism.